Biogen to buy from Pfizer an asset to develop into potential Alzheimer's, Parkinson's treatmentsMarket Watch • 01/13/20
Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc.GlobeNewsWire • 01/13/20
Red-Hot Biotech Stocks Brace For Key Meeting — Here's What To ExpectInvestors Business Daily • 01/09/20
Biogen to discontinue development of treatment for rare brain disorder after trial misses goalsMarket Watch • 12/13/19
Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear PalsyGlobeNewsWire • 12/13/19